United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $499.03, for a total transaction of $4,740,785.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $161,906,790.29. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Performance

NASDAQ:UTHR traded up $8.85 during mid-day trading on Wednesday, hitting $506.82. The stock had a trading volume of 453,080 shares, compared to its average volume of 493,903. United Therapeutics Corporation has a twelve month low of $395.00 and a twelve month high of $609.35. The stock has a market cap of $21.74 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 2.43 and a beta of 0.56. The company’s 50 day simple moving average is $523.93 and its 200 day simple moving average is $540.20.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the previous year, the business earned $6.41 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on UTHR. Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada decreased their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in UTHR. Arjuna Capital boosted its position in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares during the period. Sage Rhino Capital LLC increased its position in United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC raised its stake in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance boosted its holdings in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.